Tariff exposure $400M FY26, Q1 beat & steady guidance amid restruct 7k/new CEO/oversold & valuation debate
Key Questions
What is the current stock price of Procter & Gamble (PG) and its recent performance?
Procter & Gamble's stock is trading at $141.30, down 1% on the day and lagging 8% over the past month. This underperformance occurs amid broader market gains, as noted in recent Zacks reports.
What is Procter & Gamble's tariff exposure for FY26?
Procter & Gamble faces a tariff exposure of $400M in FY26. This factor remains a key watchpoint even after recent earnings beats, according to market analyses.
How did Procter & Gamble perform in its latest Q1 earnings?
Procter & Gamble beat Q1 earnings expectations with steady guidance maintained. The company is navigating restructuring and other headwinds while confirming positive outlooks.
What restructuring efforts is Procter & Gamble undertaking?
Procter & Gamble is undergoing restructuring that includes approximately 7,000 positions. This is part of broader strategic changes under new leadership.
What are the latest analyst ratings and price targets for PG stock?
UBS maintains a Buy rating with a $166 target (cut from $170), TD Cowen has a Hold at $142 citing oil impacts, and Zacks ranks it #3 Hold. These reflect a premium P/E of 20.5x amid valuation debates.
What are Zacks' confirmed earnings estimates for PG's Q3?
Zacks confirms Q3 estimates at EPS $1.57 (up 2%) and revenue $20.6B (up 4%). Investors are reassessing ahead of the report amid pricing and innovation dynamics.
Is Procter & Gamble's stock considered oversold, and what is the valuation debate?
PG stock is viewed as potentially oversold with lagging performance, sparking valuation debates. At a P/E of 20.5x, it's seen as premium, balancing pricing pushback against innovation offsets and dividend strength.
How might oil prices and dividends factor into PG stock ahead of Q3?
Rising oil prices pose risks, as noted by TD Cowen, but PG's resilient dividend profile offers a hedge. Investors are reassessing re-rating potential, dividend safety, and oil impacts pre-Q3.
Stock $141.30 (-1% day/-8% mth lag); Zacks confirms Q3 4/24 ests EPS$1.57(+2%)/rev$20.6B(+4%); UBS Buy$166 (cut $170)/TD$142 Hold (oil)/Zacks#3 Hold P/E20.5x premium; pricing pushback vs innovation offsets; reassess re-rating/div/oil pre-Q3.